With a market-beating yield, accelerating dividend growth, and the potential that shares are 29% undervalued, this could be a rare opportunity to buy Merck $MRK)--an above-average business for a below-average price. See @JasonFieber latest UDGSOW pick. https://t.co/Egm0i3mhCX https://t.co/akYJA8Chpw